The U.S. Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP) has awarded a $4 million-plus grant to the Israeli company MeMed to support the transition of MeMed’s prototype point-of-care (POC) platform toward a final product, including transfer to manufacturing and implementation of cloud connectivity. MeMed’s POC test is designed to support clinicians in determining whether an infection is bacterial or viral in order to decide whether to treat with antibiotics. The company recently completed three clinical studies of its prototype, two of which were double-blind, which collectively enrolled 2,376 patients. The latest study, Pathfinder, was published in the journal of the American Academy of Pediatrics and independently confirmed that MeMed’s test distinguishes between bacterial and viral infections in children. The CDMRP grant complements a $9.2 million contract from the Defense Threat Reduction Agency awarded last year to MeMed that is supporting the final stages of prototype development.